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ABSTRACT: Endothelial microparticles (EMPs) are endothelium-derived submicron vesicles that are released in re-
sponse to diverse stimuli and are elevated in cardiovascular disease, which is correlatedwith risk factors. This study
investigates the effect of EMPs on endothelial cell function and dysfunction in a model of free fatty acid (FFA)
palmitate-induced oxidative stress. EMPswere generated fromTNF-a-stimulatedHUVECs andquantified by using
flow cytometry. HUVECs were treated with and without palmitate in the presence or absence of EMPs. EMPs were
found to carry functional eNOS and to protect against oxidative stress by positively regulating eNOS/Akt signaling,
which restored NO production, increased superoxide dismutase and catalase, and suppressed NADPH oxidase and
reactive oxygen species (ROS) production, with the involvement of NF-erythroid 2-related factor 2 and heme
oxygenase-1. Conversely, under normal conditions, EMPs reduced NO release and increased ROS and redox-
sensitive marker expression. In addition, functional assays using EMP-treated mouse aortic rings that were per-
formedunderhomeostatic conditionsdemonstratedadecline inendothelium-dependentvasodilatation,but restored
the functional response under lipid-induced oxidative stress. These data indicate that EMPsharbor functional eNOS
and potentially play a role in the feedback loop of damage and repair during homeostasis, but are also effective in
protecting against FFA-induced oxidative stress; thus, EMP function is reflected by the microenvironment.—
Mahmoud, A. M., Wilkinson, F. L., McCarthy, E. M., Moreno-Martinez, D., Langford-Smith, A., Romero, M.,
Duarte, J., Alexander, M. Y. Endothelial microparticles prevent lipid-induced endothelial damage via Akt/eNOS
signaling and reduced oxidative stress. FASEB J. 31, 4636–4648 (2017). www.fasebj.org
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Endothelial dysfunction underpins the progression of car-
diovasculardisease (1,2)and ispresent inpatientswith type
2 diabetes (3). Classic hallmarks of endothelial dysfunction
are reduced NO bioavailability, impaired endothelial-
mediated vasorelaxation, inflammation, elevated reactive
oxygen species (ROS), hemodynamic deregulation, and
high circulating levels of free fatty acids (FFAs) (4–7).
Palmitate—the main saturated FFA in the bloodstream—
induces ROS production in the vasculature via increased
levels and activity of NADPH oxidases, mitochondrial
uncoupling (8, 9) and down-regulation of eNOS (10).
NF-erythroid 2–related factor 2 (Nrf2), a redox-sensitive
transcription factor, is crucial for the regulation of the
expression of various antioxidant genes via binding to
the antioxidant response element (ARE) that is present
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in NAD(P)H:quinone oxido-reductase 1 (NQO1), heme
oxygenase-1 (HO-1), glutathione peroxidase, and the
superoxide dismutase (SOD) family (11–13).
The term “extracellular vesicles” has been used to in-
clude 3 categories of extracellular microparticles (MPs);
apoptotic bodies, microvesicles/MPs, and exosomes,
depending on their size. Microvesicles are gaining interest
as cell-derived sealed membrane vesicles that act as vehi-
cles for the intercellular transfer of mRNAs, microRNAs,
lipids, and proteins, and reflecting their cell of origin. This
allows cell communication either in a paracrine or
endocrine fashion. MPs are small-membrane vesicles
(100–1000 nm) that are released from different cell types
under adverse conditions, including turbulent flow and
proapoptotic stimulation (14).MPs can also be released in
small numbers under basal physiologic conditions (15).
Our laboratoryhas focused, in particular, on100–1000nm
microvesicles that are released from endothelial cells,
which we describe as endothelial microparticles (EMPs)
(16–20). Although eNOS has been identified on EMPs
(21), there is no evidence that supports functional eNOS
activity (22), which we now show for the first time. MPs
have been reported to be taken up by either membrane
fusion, receptor-mediated cell signaling, or phagocytosis
(23, 24) and are now recognized as important circulating
biologic vectors with potential as surrogate markers for
multiple pathophysiologic conditions (25). Indeed, EMPs
have been associated with several cardiovascular risk
factors (26), as well as increased production of ROS in rat
aortic rings (27) and endothelial cells in vitro (28, 29).
Despite links with impaired endothelial function (28)
and apoptosis (30), EMPs have also been reported to
protect endothelial cells against damage by promoting
cell survival via induction of cytoprotective and anti-
inflammatory effects (17, 18, 31).
We hypothesize that EMPs have a dual function
depending on the physiologic conditions. We used an in
vitro and ex vivo endothelial cell model of lipid-induced
oxidative stress by treating HUVECs and mouse aortic
rings with palmitate and investigated several parameters
after exposure to EMPs in terms of endothelial signaling
and function, which may be triggered in the process.
MATERIALS AND METHODS
HUVEC culture
HUVECs from pooled donors (Caltag Medsystems, Bucking-
ham, United Kingdom) were cultured in Medium 199 (Lonza,
Brussels, Belgium) thatwas supplementedwith 20% fetal bovine
serum, penicillin/streptomycin (2 mM), glutamine (2 mM),
HEPES (10 mM), endothelial cell growth supplement
(30 mg/ml), and heparin (100 mg/ml) under 5% CO2 at 37°C.
Experiments were repeated in 3 different populations of
HUVECs from passage 2 to 7, with no differences observed
between passages or populations.
Generation and isolation of EMPs
Confluent HUVECs were incubated in complete medium and
treatedwith10ng/mlTNF-a (PromoCell,Heidelberg,Germany)
for 24 h under 5% CO2 at 37°C. Conditioned medium was col-
lected and cleared from detached cells and cell fragments by
centrifugation at 4300 g for 5 min at room temperature. Su-
pernatants were transferred to thick-wall polycarbonate ul-
tracentrifugation tubes (Beckman Coulter, High Wycombe,
United Kingdom) and centrifuged at 105 g for 2 h at 4°C using
an Optima XE ultracentrifuge (Beckman Coulter), as described
previously (32). Pellets were carefully washed in PBS and
centrifuged again under the same conditions. Washed pellets
that contained MPs were resuspended in PBS. As such, the
preparation may contain microvesicles/exosomes. We define
EMPs in thismanuscript specifically by themembrane particles
from the cell of origin after this centrifugation step.
EMP quantification was carried out by using an established
protocol in our laboratory (17). See the Supplemental Data for
details.
Confirmation of EMP purity
Simultaneous incubation for 15 min with fluorescent Abs was
performed by using 2.5 ml of phycoerythrin-conjugated anti-
human CD31 (55546; BD Pharmingen, San Diego, CA, USA),
2.5ml of allophycocyanin-conjugatedanti-humanCD42b (551061;
BD Pharmingen), and 5 ml of FITC-conjugated anti-human
annexin-V marker (51-65874X; BD Pharmingen). Flow cytom-
etry was performed on prepared samples by using a FACSVerse
flowcytometer (BDBiosciences,San Jose,CA,USA).Analysiswas
stopped once 1000 beads had been counted, and gateswere set to
excludeartifacts andbeads. Events thatwerepositive for annexin-
V (MP marker) and CD31 (endothelial marker) and negative for
CD42b (platelet-marker; annexin- V+/CD31+/CD42b2) were
defined as EMPs. The purity of this isolation is .98%, which
indicates that the isolated MPs are of endothelial cell origin.
Palmitate and EMP treatment
Lipid-containing media were prepared by conjugation of so-
dium palmitate to bovine serum albumin (BSA) according to
Chavez and Summers (33), with some modifications. In brief,
palmitatewas dissolved in ethanol in a 60°Cwater bath before
diluting 1:100 in M199 that contained 2% (wt/vol) fatty acid-
free BSA and prewarmed for 1 h at 37°C. On the basis of our
initial optimization studies (34) and our previous workwhere
levels of 105 and 106 EMPs/ml were detected in patients with
systemic lupus erythematosus (17) and carotid artery disease
(19), respectively, these 2 doseswere chosen for EMP treatment.
A concentration of 105 EMPs/ml was also used to assess for a
concentration–dose response. Therefore, 53 103 HUVECs/cm2
(confluent) were cultured in complete medium and treated
with 105 or 106 EMPs/ml for 24 h or coincubatedwith palmitate
(100 mM) for 24 h, or with palmitate added for the last 3 h of
the incubation period. Control cells were incubated in serum-
free M199 that contained 2% (wt/vol) fatty acid-free BSA.
Assay of NO release by HUVECs and EMPs
NO released by HUVECs was quantified by using the NO-
sensitive fluorescent probe, diaminofluorescein-2 (DAF-2), as
described previously (35). After incubation, cells were washed
with PBS and preincubated with L-arginine (100 mM in PBS) for
5 min at 37°C. In some experiments, L-NAME (N-nitroarginine
methyl ester; 100 mM) was added 20 min before the addition of
L-arginine. Cells were then incubated with DAF-2 (0.1 mM) for
2 min, followed by the calcium ionophore, calimycin (A23187;
1 mM), for 30 min. Fluorescence intensity (arbitrary units) was
measured by using a microplate reader (BioTek Instruments,
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Winooski, VT, USA), and autofluorescence was subtracted from
each value. The difference between fluorescence signal with and
without L-NAMEwas considered NO production.
The same procedure was followed to assay the NO release
fromEMPs thatwere resuspended inPBSat 105 and106/well of a
96-well plate.
Assay of intracellular ROS production
Confluent HUVECs (96-well plates) were incubated with
10 mM of the fluorescent probe, CMH2DCF-DA (29-79-
dichlorodihydrofluorescein diacetate; Sigma-Aldrich, St. Louis,
MO, USA), for 30 min at 37°C. Fluorescence intensity was
measured at excitation 490 nm and emission 540 nm by using a
microplate reader (BioTek Instruments).
Assay of NADPH oxidase activity
HUVECs andmouse aortic rings were incubated with 105 or 106
EMPs for 24 h in the presence or absence of palmitate. Palmitate
treatment was performed as the model of chronic or acute lipid-
induced oxidative stress either for 24 h in coculturewith EMPsor
simply as a final 3-h stimulation in EMP-pretreated HUVECs
before harvesting at 24 h, respectively. NADPH-enhanced su-
peroxide (O2
×2) release in homogenates from cultured HUVECs
or mouse aortic rings was quantified by lucigenin-enhanced
chemiluminescence, as previously described (36).
Measurement of lipid peroxidation
Malondialdehyde (MDA)—an index for determining the extent
of lipid peroxidation—was measured by using OxiSelect thio-
barbituric acid reactive species assay kit (Cell Biolabs, SanDiego,
CA, USA) according to manufacturer instructions. To prevent
artifactual oxidation of lipids during sample processing and the
thiobarbituric acid reaction,weaddedbutylatedhydroxytoluene
to the thiobarbituric acid reagent and samples.
Determination of SOD and catalase activity
SOD and catalase (CAT) activity was determined in HUVEC
homogenate by using Cayman’s assay kits (Cayman Chemical,
Ann Arbor, MI, USA).
RNA isolation and RT-PCR analysis
Total RNAwas extracted fromHUVECs by using Trizol reagent
(Thermo Fisher Scientific, Waltham, MA, USA). RNA samples
were quantified at 260 nm. RNA samples with A260/A280 ratios
$1.7 were selected. First-strand cDNAs were synthesized from
2mg total RNA by using SuperScript II reverse transcriptase and
oligo deoxythymidine primers (Sigma-Aldrich). Reverse tran-
scription was performed with a Surecycler 8800 thermocycler
(Agilent Technologies, Santa Clara, CA, USA), and reverse
transcription products were amplified by SYBR Green master
mix (BioLine, London, United Kingdom) in a total volume of
20ml byusing theprimer set andconditionsdescribedpreviously
(36) (Supplemental Data). Housekeeping gene GAPDH (glycer-
aldehyde 3-phosphate dehydrogenase) was used for normaliz-
ing gene expression.
Western blot analysis
Total protein extracts were harvested fromHUVECs and EMPs,
lysed in RIPA buffer, supplemented with proteinase inhibitors,
and analyzed by Western blotting as previously described (37)
(Supplemental Data).
Ex vivo assessment of mouse aortic ring
vascular reactivity
Thoracic aortas were obtained frommale BALB/cmice (Janvier,
St. Berthevin Cedex, France). All procedures conformed to the
Guide for the Care and Use of Laboratory Animals and were
approved by the Institutional Committee for the Ethical Care of
Animals (University of Granada, Granada, Spain). Wire myog-
raphy experiments were performed as previously described (37)
(Supplemental Data).
Statistical analysis
Statistical analysis was performed by using Prism 5 (GraphPad
Software, La Jolla, CA, USA) using 1-way ANOVA and Tukey’s
post hoc analysis. A 2-factor ANOVA was used to test for group
interactions. Resultswereexpressed asmeans6 SEM andP, 0.05
was considered significant. The number of independent experi-
ments performed are stated in the figure legends.
RESULTS
EMPs carry a functional eNOS enzyme
To determine whether EMPs carry functional eNOS, 2
doses—105 and 106 EMPs—were incubated with the
eNOS substrate, L-arginine, for 5min at 37°C, followed by
addition of DAF-2 to assay basal NO production. eNOS
was then stimulatedwith theCa2+ ionophore,A23187, and
NO production was determined after 5, 15, and 30 min.
EMPs causedan increase in eNOS-derivedNOproduction
in both doses, whereas addition of the NOS inhibitor,
L-NAME, significantly impaired A23187-stimulated NO
production (P, 0.001; Fig. 1A and Supplemental Fig. 1A).
The presence of peNOS in EMPs was further assessed
by Western blot analysis using HUVECs as a control.
peNOSSer1177 and total eNOS were detected in the EMP
lysate (Fig. 1B).
EMPs have differential effects on NO
production in HUVECs depending on the
presence or absence of oxidative stress
Wenext established theeffects ofEMPsonHUVECsunder
normal conditions and FFA-induced oxidative stress by
incubation with palmitate. To determine whether the du-
ration of oxidative stress was important and whether
EMPs exerted a protective or restorative effect under these
conditions, NO production was measured in 5 treatment
groups: 1) HUVECs thatwere treatedwith EMPs alone for
3 h; 2) HUVECs in the combined presence of EMPs and
palmitate for 3 h; 3) HUVECs thatwere treatedwith EMPs
alone for 24 h; 4) HUVECs with EMPs in the presence of
palmitate for the last 3hofEMPtreatment; and5)HUVECs
in the combined presence of EMPs and palmitate for 24 h.
Initially, HUVECs that were incubated with either 105
or 106 EMPs for 3 h exhibited a nonsignificant effect on
NO production (Fig. 1B and Supplemental Fig. 1B), but
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sustained treatment for 24 h decreasedA23187-stimulated
NO production (P, 0.001; Fig. 1C and Supplemental Fig.
1C). As expected, palmitate-treated cells also exhibited
significantly reduced A23187-stimulated NO production
(P, 0.001; Fig. 1B, C); however, with the addition of pal-
mitate during the last 3 h or throughout the 24 h of EMP
treatment, EMPs had a restorative effect on A23187-
stimulated NO production (P, 0.001; Fig. 1C).
Figure 1. EMPs express a functional eNOS, elevate NO in palmitate (Pal)-induced HUVECs, and increase phosphorylation levels of
Akt and eNOS. A) EMPs were incubated with L-arginine for 5 min at 37°C, followed by the addition of DAF-2, and NO production
was determined. EMPs produce eNOS-derived NO in a concentration-dependent manner, which is inhibited by the NOS inhibitor,
L-NAME. The difference between ﬂuorescence signal with and without L-NAME is considered NO production. B) peNOSSer1177
expression in EMPs and HUVECs as controls. C) HUVECs that were incubated with EMPs for 3 h showed no changes in NO
production, whereas EMPs prevented the Pal-induced decline in NO production. D) Pal and EMPs diminish NO production.
Treatment with either EMPs for 24 h with the addition of Pal during the last 3 h (24 h EMPs/3 h Pal) or with EMPs and Pal for
24 h (24 h EMPs/Pal) protects against Pal-induced reduction in NO production. Results are means 6 SEM; n = 8–12. E, F)
Treatment of HUVECs with 100 mM Pal for either 3 or 24 h decreases protein phosphorylation of Akt (E) and eNOS at Ser1177 (F).
EMPs up-regulate Akt and eNOS phosphorylation in HUVECs that are treated with either EMPs for 24 h with the addition of Pal
during the last 3 h (24 h EMPs/3 h Pal) or with EMPs and Pal for 24 h (24 h EMPs/Pal). Results are means 6 SEM; n = 6 and
analyzed using 1-way ANOVA. AUC, area under curve; ns, nonsigniﬁcant. *P , 0.05, **P , 0.01, ***P , 0.001.
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EMPs modulate mRNA and phosphorylation
levels of eNOS and Akt under palmitate-
induced oxidative stress
Previous studies have shown that eNOS acts via the PI3K
pathway in endothelial cells (38, 39); therefore, to de-
termine whether this pathway is modulated by EMP
treatment, HUVECs were incubated with EMPs for 24 h
and demonstrated no significant change in either eNOS
and Akt mRNA expression (Supplemental Fig. 2) or pro-
tein phosphorylation (Fig. 1D, E). Palmitate treatment
produced amarked decline in bothAkt and eNOSmRNA
and protein phosphorylation, whichwas rescued by EMP
treatment under conditions of short-term (3 h) or long-
term (24 h) oxidative stress (P, 0.001).
EMPs protect against palmitate-induced ROS
production and oxidative stress in vitro
We next investigated the effect of EMPs on ROS pro-
duction, lipid peroxidation, and activity of antioxidant
enzymes under homeostatic and palmitate-induced oxi-
dative stress conditions. Although EMP treatment alone
demonstrated no significant effect on ROS production in
the short term (3 h; Fig. 2A), a longer, 24-h incubation sig-
nificantly increased ROS production (Fig. 2B; P, 0.05) but
not to the levels that were achieved under palmitate-
induced oxidative stress conditions. In contrast, EMPs
significantly diminishedROS production under palmitate-
induced oxidative stress (P, 0.001; Fig. 2A, B).
Of note, EMPs alone did not alter levels of the lipid
peroxidation marker, MDA, compared with untreated
cells (Fig. 2C). In support of ROS data, MDA levels were
significantly increased (P, 0.01)underpalmitate-induced
oxidative stress, an effect that was significantly reduced
after the administration of EMPs at both 105 (P, 0.05) and
106 (P, 0.01) doses.
EMP treatment alone demonstrated no difference in
SOD andCAT activity compared with controls. Palmitate
induced a significant decrease in the activity of both SOD
(P , 0.01) and CAT (P , 0.001), which was rescued by
EMP treatment (Fig. 2D, E).
EMPs modulate NADPH oxidase activity in
HUVECs in response to oxidative stress
To further interrogate themechanismof EMP reduction of
oxidative stress, the NADPH oxidase pathway was in-
vestigated. Although the 105 EMP dose had no effect on
NADPH oxidase activity over 24 h, the 106 dose signifi-
cantly increased enzyme activity compared with controls
(P , 0.05; Fig. 3A). Short- and long-term palmitate-
induced oxidative stress conditions produced a significant
increase in NADPH oxidase activity (P , 0.001), which
was significantly decreased after EMP treatment at both
doses (P, 0.01).
EMP treatment at the 105 dose had no effect on mRNA
abundance of the NADPH oxidase subunits, NOX4,
NOX1, p47phox and p22phox, whereas the 106 dose signifi-
cantly increased mRNA expression of NOX4 (P , 0.05),
NOX1 (P, 0.05), p47phox (P, 0.01), and p22phox (P, 0.01;
Fig. 3B). Palmitate-induced oxidative stress conditions
produced a significant up-regulation of NOX4 (P ,
0.01), NOX1 (P, 0.001), p47phox (P, 0.001), and p22phox
(P , 0.001), which were all significantly down-regulated
after EMP treatment under the same conditions.
Beneficial effects of EMPs against
palmitate-induced oxidative stress via
the Nrf2/ARE pathway in vitro
To evaluate whether the downstream NRF2/ARE
pathways are involved in the antioxidant effects of
EMPs under oxidative stress conditions, mRNA and
protein expression of Nrf2, NQO1, and HO-1 was de-
termined by using quantitative RT-PCR and Western
blotting, respectively (Fig. 4). EMP treatment at the 105
dose for 24 h showed no change in Nrf2 mRNA abun-
dance; however, Nrf2 protein levels were significantly
decreased (P , 0.05). The 106 EMP dose significantly
decreased both Nrf2 mRNA (Fig. 4A) and protein (Fig.
4D) levels. Under short- and long-term palmitate-
induced oxidative stress conditions, a significant re-
duction inNrf2mRNAand protein levelswas observed
compared with homeostatic controls; however, EMPs
under oxidative stress conditions caused a significant
attenuation of this effect, inwhichNrf2mRNAabundance
was higher, whereas Nrf2 protein levels, although slightly
increased, were not significantly different compared with
palmitate-treated cells.
NQO1 exhibited a similar expression pattern. Both 105
and 106 EMP doses significantly decreased the expression
of both NQO1 gene and protein (Fig. 4B, E; P , 0.001).
Palmitate-induced oxidative stress conditions also signif-
icantly diminished the mRNA and protein expression
levels of NQO1 (P, 0.001), an effect thatwas abolished in
the presence of EMPs.
HO-1expressionalso followed thispattern.mRNAwas
significantly decreased (P , 0.001) after 105 EMP treat-
ment, whereas its protein level was unaffected. Treatment
with 106 EMPs for 24 h significantly reduced the mRNA
(P, 0.001) and protein (P, 0.01) expression ofHO-1 (Fig.
4C, F). A significant decrease in both HO-1 gene and
mRNA and protein expression was observed under oxi-
dative stress conditions (P , 0.001) with a marked up-
regulation in the presence of EMPs in a dose-dependent
manner.
EMPs restore endothelium-dependent
vasodilatation and NADPH oxidase ex vivo
To validate in vitro studies in an ex vivo model, con-
tractile analysis was performed in mouse aortic vessels.
Aortas that were treated with 105 EMPs demonstrated
no significant difference in endothelium-dependent
vasodilator responses to acetylcholine (ACh) com-
pared with control aortas (Fig. 5A); however, an in-
creased dose of 106 EMPs produced a significant decline
in endothelium-dependent vasodilatation (Fig. 5B; P,
0.001). Palmitate-induced oxidative stress conditions
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Figure 2. Effects of EMPs and/or palmitate (Pal) on ROS production and oxidative stress in HUVECs. A) EMPs produce no effect
on ROS production from HUVECs after a 3-h treatment period, but exhibit a signiﬁcant protective effect after Pal-induced
oxidative stress. B) EMPs signiﬁcantly increase ROS production after treatment for 24 h, but with the addition of Pal during the
last 3 h (24 h EMPs/3 h Pal), or with EMPs and Pal for either 3 or 24 h (24 h EMPs/Pal), EMPs protect against Pal-induced ROS
production. C–E) HUVECs that were treated with Pal for 3 and 24 h demonstrated a signiﬁcant increase in MDA, a marker of
lipid peroxidation (C), and concomitant decrease in the activity of SOD (D) and CAT (E). EMPs prevent Pal-induced lipid
peroxidation and diminished the activity of antioxidant enzymes in HUVECs that were treated with either EMPs for 24 h with the
addition of Pal during the last 3 h (24 h EMPs/3 h Pal) or with EMPs and Pal for 24 h (24 h EMPs/Pal). Results are means 6 SEM;
n = 6–10 and analyzed using 1-way ANOVA. AU, arbitrary unit. *P , 0.05, **P , 0.01, ***P , 0.001.
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over24hsignificantlydiminishedendothelium-dependent
vasodilator responses to ACh, as expected (P, 0.001),
and both doses of EMPs significantly attenuated this effect
(P , 0.001). To validate the endothelial-dependent
relaxation responses to ACh, the NOS inhibitor L-NAME
wasadded,whichabolished the relaxant response thatwas
induced by ACh in all experimental groups as shown in
Supplemental Fig. 3.
Figure 3. Effects of EMPs and/or palmitate (Pal) on NADPH oxidase in HUVECs. NADPH oxidase activity measured by lucigenin-
enhanced chemiluminescence. Expression of NADPH oxidase subunits, NOX-4, NOX-1, p22phox, and p47phox, at the level of mRNA
by RT-PCR. Palmitate and EMPs (106) increase both NADPH oxidase activity (A) and expression of the enzyme subunits (B). EMPs
reduce Pal-induced NADPH oxidase activation and expression in HUVECs that are treated with either EMPs for 24 h with
the addition of Pal during the last 3 h (24 h EMPs/3 h Pal) or with EMPs and Pal for 24 h (24 h EMPs/Pal). Results are means6 SEM;
n = 6–8 and analyzed using 1-way ANOVA. RLU, relative luminescence units. *P , 0.05; **P , 0.01; ***P , 0.001.
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To examine whether ROS are involved in endothelial
dysfunction induced by EMPs (Fig. 5C) and palmitate-
induced oxidative stress conditions (Fig. 5D) in mouse
aorta, the endothelium-dependent relaxant response to
ACh in the presence of the mitochondrial antioxidant,
mitoQ, or the NADPH oxidase inhibitor, apocynin, were
analyzed. Both mitoQ and apocynin significantly im-
proved the impaired aortic relaxation in response to ACh
induced by EMPs or palmitate.
NADPH oxidase activity as measured by lucigenin-
enhanced chemiluminescence (Fig. 5E) was also signifi-
cantly increased by both EMPs and palmitate, an effect
that was more pronounced in the presence of palmitate;
however, under palmitate-induced oxidative stress con-
ditions, EMPs attenuated the effect, producing a signifi-
cant decrease in the activity ofNADPHoxidase compared
with oxidative stress conditions alone (P, 0.001).
DISCUSSION
To our knowledge, this is the first report to demon-
strate that EMPs restore the lipid-induced impairment
of endothelium-dependent vasodilation and NO pro-
duction. Moreover, these data point to the possible
involvement of Akt/eNOS and Nrf2/ARE pathways
in mediating the effects of EMPs on the endothelium.
We also suggest when and how EMPs exert pathologic
or protective effects on the endothelium.
Although Horn et al. (40) have suggested that circulat-
ing MPs retain functional eNOS by using immunopre-
cipitation, Western blot analysis, a Griess assay, and the
fluorescent probe MNIP-Cu, we strengthen and expand
these data by confirming more directly the presence of a
functional eNOS by using the NO-sensitive fluorescent
probe, DAF-2, and a specific pharmacologic inhibitor of
NOS, L-NAME, that significantly prevented A23187-
stimulated NO production from EMPs.
Although a short-term exposure of HUVECs to EMPs
produced no change in A23187-stimulated NO pro-
duction, amore sustainedexposureofHUVECswithboth
dosesofEMPsmarkedlydiminishedNOproduction.This
suggests that other factors in the EMPs could mask the
ability of EMP eNOS to function, which causes a decrease
in eNOS activity and NO generation. Our data also add
strength to the findings of Brodsky et al. (27), who first
reported thatEMPsdecreasedNOproduction in rat aortic
rings, an effect that was attributed to increased O2
×2
production.
In our palmitate-induced model of oxidative stress, we
demonstrated diminished NO production via reduced
Akt-dependentphosphorylationof eNOSat Ser1177,which
supports the findings of previous reports (41, 42); how-
ever, the damaging effect of palmitate was attenuated
Figure 4. Effects of EMPs and/or palmitate (Pal) on Nrf2/ARE pathway in HUVECs. A–F) Effect of EMPs and/or Pal treatment
on HUVECs with regard to Nrf2 (A, D), NQO-1 (B, E), and HO-1 (C, F) levels was determined by using quantitative RT-PCR and
Western blotting. Treatment with either EMPs or Pal produces a signiﬁcant decrease in both mRNA (A–C) and protein (D–F)
expression of Nrf2, NQO1, and HO-1. EMPs increase expression of Nrf2, NQO1, and HO-1 in HUVECs that are treated with
either EMPs for 24 h with the addition of Pal during the last 3 h (24 h EMPs/3 h Pal) or with EMPs and Pal for 24 h (24 h EMPs/Pal).
Results are means 6 SEM; n = 6 and analyzed using 1-way ANOVA. *P , 0.05, **P , 0.01, ***P , 0.001.
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when HUVECs were coincubated with EMPs. EMPs pre-
vented the palmitate-induced decline in NO production
via phosphorylation of both Akt and eNOS; therefore,
EMPs exert paradoxical effects on eNOS activity and NO
production in endothelial cells.While inducing endothelial
cell damage to healthy cells, under an FFA insult, EMPs act
to restore NO bioavailability.
It is well established that ROS scavenges NO and acti-
vates membrane oxidases, which increases the level
of asymmetric dimethylarginine—an arginine decoy for
Figure 5. Effects of EMPs and/or palmitate (Pal) on endothelium-dependent vasodilatation and NADPH oxidase in mouse
aortas. A, B) Treatment of aortic rings with either 106 EMPs or Pal for 24 h diminished endothelium-dependent vasodilator
responses to ACh. EMPs at both 105 (A) and 106 (B) doses improve the Pal-reduced endothelium-dependent vasodilatation. C, D)
ROS are involved in endothelial dysfunction induced by EMPs (C) and Pal (D). MitoQ and apocynin improve the impaired aortic
relaxation in response to ACh, induced by EMPs or Pal. E) NADPH oxidase activity increases in aortic rings that are treated with
either EMPs or Pal for 24 h. In the presence of Pal, EMPs decrease NADPH oxidase activity. Results are means 6 SEM; n = 8–12.
Data in panels A–D were analyzed using 2-way ANOVA and in panel E using 1-way ANOVA. CT, control; RLU, relative
luminescence units. *P , 0.05; **P , 0.01; ***P , 0.001.
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active sites on eNOS and L-arginine transporters (43). In
light of the fact that an increased production of O2
×2 could
play a role in the reduced bioavailability of NO (44), we
investigated the effects of EMPs on ROS production. Our
data demonstrate that under healthy conditions, EMPs
had little effect on ROS production, levels of lipid perox-
idation, or the activity of the antioxidant enzymes, SOD
and CAT. We also demonstrated the validity of our oxi-
dative stress model in that palmitate-enhanced ROS pro-
duction, increased the lipid peroxidation product, MDA,
and decreased the activity of the antioxidant enzymes,
SOD and CAT. These effects were attenuated by EMPs.
The potentiation of antioxidant defenses and normaliza-
tion of ROS contributed to the restoration of endothelial
function.
Another major player in ROS generation in the vascu-
lature includesNADPHoxidases, and it has been reported
that FFAs induce ROS production in the endothelium by
increasing the activity of NADPH oxidases (8, 45). Here,
we demonstrated that FFA increased the activity of
NADPH oxidase, which correlated with an increased ex-
pression of itsNOX1,NOX4,p22phox, andp47phox subunits.
Of interest, EMPs protected against these effects and re-
duced NADPH oxidase activity, which correlated with
reduced expression of NOX subunits.
To probe the downstream targets of ROS, we in-
vestigated the antioxidant transcription factor Nrf2/ARE
pathway. Nrf2 is essential in cytoprotective mechanisms
against oxidative stress and operates via transcriptional
activation of ARE-dependent expression of antioxidant
genes, including HO-1, NQO-1, SOD, and CAT (46, 47).
We observed a significant decline in Nrf2 and its down-
stream genes and proteins when cells were treated with
either EMPs or palmitate alone. Mann et al. (48) proposed
that the basal activity of NADPH oxidase produces ROS,
thereby activating Nrf2/ARE-mediated antioxidant gene
expression to maintain redox homeostasis; however, we
suggest that superfluous ROS production could lead to
Nrf2 down-regulation in normal physiologic conditions.
This hypothesis is based on the results of multiple studies
that have demonstrated inhibition of the Nrf2 pathway
under oxidative stress conditions. For example, Liu et al.
(49) reported that oscillating high glucose enhanced oxi-
dative stress and apoptosis in human coronary artery en-
dothelial cells as a result of the inhibition of theNrf2-HO-1
pathway. Mahmoud and Al Dera (50) demonstrated that
cyclophosphamide-induced oxidative stress significantly
abolished the activation of the liverNrf2pathway. Finally,
the Mann laboratory has also shown that disturbed shear
stress on the vascular wall, which results from oscillatory
blood flow, diminishes the Nrf2-mediated activation of
ARE-linked genes (51). Moreover, we have recently re-
ported that palmitate down-regulated the Nrf2/ARE/
HO-1 signaling pathway in HUVECs (37).
In contrast, under palmitate insult, we observed
that EMPs significantly activated Nrf2 and its down-
stream proteins, HO-1 andNQO-1. This could explain,
in part, the protective mechanism of EMPs against
lipid-induced endothelial dysfunction, which sup-
ports the findings of other studies (52, 53) where, for
example, HO-1 is known to degrade the pro-oxidant
heme to biliverdin, which is subsequently converted to
the radical scavenger, bilirubin (54). Bilirubin, in turn,
may directly inhibit NADPH oxidase by interrupting
the assembly and activation of the enzyme in endo-
thelial cells both in vitro and in vivo (55, 56). Further-
more, interplay between Nrf2 and eNOS is not fully
understood. Activation of Nrf2 by CDDO-IM (2-cyano-
3,12-dioxooleana-1,9-dien-28-oic imidazolide) increased
theamountofbioavailableNOinHUVECs (57).Activation
of Nrf2 enhanced NO generation in human glomerular
endothelial cells, as recently reported by Luo et al.
(58). Mann et al. (48) and Fledderus et al. (59) hypothe-
sized that augmented eNOS activity enhances ARE-
linked gene transcription.
Having demonstrated a clear protectivemechanism
for EMPs under oxidative stress in vitro, the same ex-
perimental design was carried out ex vivo in mouse
aortic rings. Previous studies have demonstrated im-
paired ACh-induced relaxation in mouse aorta that
was treated with T lymphocyte-derived MPs via acti-
vation of xanthine oxidase-induced ROS (60). In
addition, Boulanger et al. (61) reported diminished
endothelial NO-mediated relaxation in normal rat
aortic rings that were treated with circulating MPs
from patients with myocardial infarction. Here, we
showed that the inhibition of NADPH oxidase and
mitochondrial ROS production by the pharmacologic
agents, apocynin andmitoQ, respectively, reduced the
ability of EMPs to diminish ACh-induced relaxation.
These results suggest that EMPs exert their effects on
ROS production and vascular relaxation, mainly via
ROS produced by NADPH oxidase and mitochondria.
Our findings were further validated ex vivo by the in-
creased activity of NADPH oxidase in EMP-treated
mouse aortic rings.
Under palmitate-induced oxidative stress, mouse
aortic rings exhibited impaired ACh-induced re-
laxation. Previous research from theDuarte laboratory
has demonstrated that palmitate-induced endothelial
dysfunction is associated with increased ROS pro-
duction (41). Use of the NADPH oxidase inhibitor,
apocynin, and the mitochondrial antioxidant, mitoQ,
partially counteracted the palmitate-induced impair-
ment of endothelium-dependent relaxation, which
strengthened their findings (41); however, in accor-
dance with our in vitro studies, EMPs effectively
improved endothelium-dependent relaxation and de-
creased the activity of NADPH oxidase in palmitate-
induced mouse aortas. In light of these data, it seems
likely that EMPs improved vascular reactivity via in-
hibition of ROS production and an increased NO
bioavailability. Incubation of aortic rings from all
experimental groups with a high concentration of the
NOS inhibitor, L-NAME, almost abolished ACh-
induced relaxation, which indicated that it is completely
dependent on eNOS-derived NO.
Our findings raise a number of key questions that
future work will help to explore. Foremost is identifi-
cation of the bioactive mediators that are contained
within EMPs. Screening EMPs for microRNAs and
proteins may clarify the different effects observed in
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our experiments. EMPs are produced under homeo-
static conditions, albeit not in the quantities used in
our experiments (61), and different conditions may
alter their behavior. Classically, EMPs have been
considered to be pathogenicmediators, butwe suggest
that, in fact, they have a dual role that is aimed at
maintaining endothelial health under conditions of
stress, while also potentially being pathogenic,
depending on their environment. In support of this,
whereas EMPs are elevated in cardiovascular disease
(26), they have been shown to be protective in sepsis
(62), which suggests that their number and role alters
depending on the pathologic insult. In addition, how
EMPs interact with target cells may reveal them to be
therapeutic targets to modify disease pathogenesis.
MPs are reported to be taken up by membrane fusion,
receptor-mediated cell signaling, or phagocytosis (23,
24). We have followed the protocol described in the
position paper by Lacroix et al. (63) to isolate EMPs
fromHUVECs, but it is likely that EMPs from different
vascular beds may have different, if not parallel, ef-
fects that will be investigated in future studies. Indeed,
all in vitromodels are limited in what we can conclude
about EMP pathophysiology, as defined by other
groups (64, 65).
Nonetheless, our results describe a novel role for EMPs.
Our mechanistic evidence suggests that this vascular
benefit is likely to result from an enhancement of Nrf2
expression, which leads to the up-regulation of enzymatic
antioxidants, attenuating ROS production and lipid per-
oxidation under high FFA conditions. Furthermore, to our
knowledge, we provide the first evidence of functional
eNOS in EMPs and its ability to generate NO. Overall, we
conclude thatEMPsarevectorsofparadoxical information
in the endothelium with a role in both health and disease
(Fig. 6); thus, EMP function is dependenton thepathologic
context and mechanisms and sites of formation. Future
work must focus on the analysis of EMP content, which
may hold unique prognostic information to stratify pa-
tients for appropriate therapy on the basis of their risk of
atherothrombotic disease.
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